pyrroles has been researched along with Mastocytosis in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| DeAngelo, DJ; Gotlib, J; Reiter, A | 1 |
| Lee, H; Li, T; Robinson, WA; Schowinsky, J; Wisell, J | 1 |
| Bochner, BS; Kuang, FL; Kudlaty, E; Perez, M; Stein, BL | 1 |
| Bose, P; Verstovsek, S | 1 |
| Afrin, LB; Choe, L; Fox, RW; Glover, SC; Zito, SL | 1 |
| Ballash, G; Fenger, J; Kovac, RL; London, C; Warry, E | 1 |
| Afrin, LB; Cichocki, FM; Molderings, GJ; Patel, K | 1 |
| Barnes, K; Cavalcanti, JVJ; Dange, RB; Hasbach, A; Patterson, J; Saavedra, PV | 1 |
| Bunting, L; Kurzman, I; London, C; McCartan, L; Robat, C; Selting, K; Stingle, N; Vail, DM | 1 |
| Carter, E; Longley, BJ; Ma, Y; McMahon, G | 1 |
1 review(s) available for pyrroles and Mastocytosis
| Article | Year |
|---|---|
New approaches to therapy for mastocytosis. A case for treatment with kit kinase inhibitors.
Topics: Amino Acid Substitution; Combined Modality Therapy; Drug Design; Enzyme Activation; Enzyme Inhibitors; Feasibility Studies; Humans; Indoles; Ligands; Mast Cells; Mastocytosis; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Proto-Oncogenes; Pyrroles; Stem Cell Factor | 2000 |
1 trial(s) available for pyrroles and Mastocytosis
| Article | Year |
|---|---|
Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Indoles; Male; Mastocytosis; Protein-Tyrosine Kinases; Pyrroles; Skin Neoplasms; Vinblastine | 2012 |
8 other study(ies) available for pyrroles and Mastocytosis
| Article | Year |
|---|---|
Avapritinib for advanced systemic mastocytosis.
Topics: Humans; Mastocytosis; Mastocytosis, Systemic; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Triazines | 2022 |
Avapritinib for Cutaneous Mastocytosis.
Topics: Humans; Mastocytosis; Mastocytosis, Cutaneous; Pyrazoles; Pyrroles; Triazines | 2021 |
Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: Prompt resolution of anaphylaxis with the addition of avapritinib.
Topics: Anaphylaxis; Hematologic Neoplasms; Humans; Mast Cells; Mastocytosis; Mastocytosis, Systemic; Pyrazoles; Pyrroles; Triazines; Tryptases | 2021 |
Avapritinib for Systemic Mastocytosis.
Topics: Humans; Mast Cells; Mastocytosis; Mastocytosis, Systemic; Mutation; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Triazines | 2021 |
Successful targeted treatment of mast cell activation syndrome with tofacitinib.
Topics: Adult; Biomarkers; Female; Humans; Mastocytosis; Middle Aged; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Symptom Assessment; Treatment Outcome | 2017 |
Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib.
Topics: Animals; Antineoplastic Agents; Biomarkers; Case-Control Studies; Dog Diseases; Dogs; Female; Gastrointestinal Diseases; Indoles; Keratin-18; Male; Mastocytosis; Prospective Studies; Pyrroles; Vascular Endothelial Growth Factor A | 2018 |
Successful treatment of mast cell activation syndrome with sunitinib.
Topics: Adult; Biopsy; Duodenum; Female; Humans; Indoles; Mast Cells; Mastocytosis; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Skin depigmentation associated with toceranib phosphate in a dog.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Indoles; Male; Mastocytosis; Pyrroles; Skin; Skin Diseases; Skin Pigmentation | 2017 |